Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corporation submitted a Rule 144 notice reporting proposed transactions in Common stock. The form lists 47,280.00 (reported figure) and a separate numeric entry 575,800,000. It also shows restricted stock lapse events of 19 shares on 05/07/2025 and 574 shares on 05/07/2026.
VALERIANI NICHOLAS J reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp director Nicholas J. Valeriani received 5,127 restricted stock units as equity compensation. The award was granted on May 8, 2026 under the company’s 2020 Nonemployee Directors Stock Incentive Program and will become fully vested after one year from the grant date or at the next annual stockholders’ meeting, whichever comes first. Following this grant, he directly holds 84,423 shares of common stock. This is a non-cash, routine director compensation grant rather than an open-market share purchase.
Edwards Lifesciences Corp director Ramona Sequeira reported an equity award and updated holdings. She received a grant of 3,251 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, classified as a grant/award acquisition. After this grant, her directly held common stock position is 6,779 shares.
The filing also shows an indirect holding of 14,076 shares of Common Stock held by trust. According to the grant terms, these restricted stock units were awarded on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders.
LORANGER STEVEN R reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences director Steven R. Loranger reported equity awards and updated holdings. On May 8, 2026, he received 1,064 restricted stock units and a 3,251-share restricted stock award at $0.00 per share under the 2020 Nonemployee Directors Stock Incentive Program. Both awards are scheduled to vest 100% after the earlier of one year from the grant date or the company’s next annual stockholders’ meeting. Following these grants, he directly holds 8,997 shares and indirectly holds 75,372 shares through a trust.
LAVIOLETTE PAUL A reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp director Paul A. LaViolette received an equity grant of 3,251 restricted stock units on May 8, 2026. The award was granted at no cash price under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. These restricted stock units are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders. Following this grant, LaViolette directly holds 17,552 shares of common stock.
STONE HEISZ LESLIE reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp director Leslie Stone Heisz received a grant of 3,251 restricted stock units on May 8, 2026 under the company’s 2020 Nonemployee Directors Stock Incentive Program. These units are scheduled to become 100% vested after the earlier of one year from the grant date or the next annual meeting of stockholders. Following this award, the director holds 34,199 shares of common stock directly.
GALLAHUE KIERAN reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp director Kieran Gallahue reported equity awards on common stock. He received 1,064 restricted stock units and a 3,251-share restricted stock award on May 8, 2026 under the 2020 Nonemployee Directors Stock Incentive Program, scheduled to vest 100% after the earlier of one year from grant or the next annual stockholders meeting. Following these grants, he holds 4,315 shares directly and 79,656 shares indirectly by trust.
Feinberg David T reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp director David T. Feinberg received an equity grant of 3,251 shares of common stock in the form of restricted stock units. The award was granted at a price of $0.00 per share under the company’s 2020 Nonemployee Directors Stock Incentive Program.
The units are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or the company’s next annual meeting of stockholders. Following this grant, Feinberg holds a total of 9,087 shares of common stock directly.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported new equity awards and related tax-withholding transactions in company stock. He received 7,850 restricted stock units and 7,850 performance rights on May 7, 2026 under the company’s Long-Term Stock Incentive Compensation Program. He was also granted 44,000 employee stock options with a conversion price of $82.76 per share, vesting in approximately equal monthly installments over 36 months starting one month after grant. The restricted stock units are scheduled to vest in four equal annual installments beginning one year after grant, while the performance-based units are scheduled to vest on May 7, 2029 based on three-year performance goals.
To cover tax obligations, Bobo had 831 shares disposed at $83.20 per share on May 7, 2026 and 1,038 shares disposed at $82.76 per share on May 8, 2026, both classified as tax-withholding dispositions rather than open-market sales. Following these transactions, he directly holds 26,778.2532 shares of common stock, with additional indirect holdings of 121,756 shares via a trust and 38,969.5756 shares through a 401(k) plan.
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem reported routine share dispositions to cover tax obligations tied to equity compensation. On May 7 and 8, a total of 3,034 common shares were withheld at prices of $83.20 and $82.76 per share. These were issuer tax-withholding transactions, not open-market sales. Ullem now holds 37,914 shares directly and 266,318 shares indirectly through a trust.